Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575).
D000818:Animals; D000970:Antineoplastic Agents; D001095:Arachidonic Acids / Q000627:therapeutic use; D002460:Cell Line; D004261:DNA Replication / Q000187:drug effects; D011464:Epoprostenol / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D015289:Leukotrienes; D008054:Lipid Peroxides; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000503:physiopathology*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000503:physiopathology; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D010545:Peroxides / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use*; D047069:Pyrazolones; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D001095:Arachidonic Acids; D005343:Fibrinolytic Agents; D015289:Leukotrienes; D008054:Lipid Peroxides; D010545:Peroxides; D011720:Pyrazoles; D047069:Pyrazolones; C025086:15-hydroperoxy-5,8,11,13-eicosatetraenoic acid; D011464:Epoprostenol; D010088:Oxidoreductases; D013930:Thromboxane-A Synthase; C018845:nafazatrom